目的 调查分析2011-2015年唐山市传染病医院核苷类抗肝炎病毒药物的使用情况，为临床合理用药、药品采购提供参考。方法 回顾性分析2011-2015年唐山市传染病医院核苷类抗肝炎病毒药物使用信息，采用Microsoft Excel 2000统计分析方法，计算各类药物的销售金额、用药频度（DDDs）值及其排序、日均费用（DDC）值及其排序和药品排序比（B/A）值。结果 2011-2015年唐山市传染病医院核苷类抗肝炎病毒药物销售金额逐年增加，拉米夫定、阿德福韦酯和恩替卡韦销售额最大，三者销售额之和超过总销售额的90%。但是销售额构成比和DDDs排序变化趋势有所不同，拉米夫定和阿德福韦酯的销售金额构成比和DDDs排序呈下降趋势，而恩替卡韦呈上升趋势。富马酸替诺福韦二吡呋酯DDC值较大（DDC>100），阿德福韦酯的DDC值较小（DDC<10），5种药物的DDC均有所下降，其中富马酸替诺福韦二吡呋酯的DDC下降最显著，阿德福韦酯的DDC下降最小。各种核苷类抗肝炎病毒药物B/A值大部分接近1。结论 唐山市传染病医院核苷类抗肝炎病毒药物的用药金额呈增长趋势，临床使用日趋合理，但也存在个别药品日均费用较高、同步性较差的问题，需进一步加强管理。

Objective To investigate and analyze the usage of anti hepatitis virus nucleoside drugs in Tangshan Infectious Disease Hospital from 2011 to 2015, to provide reference for the clinically rational use of drugs and drug procurement. Methods The drug outbound data in Tangshan Infectious Disease Hospital from 2011 to 2015 were collected, and the Microsoft Excel 2000 software was used for statistical analysis. The consumption sum, defined daily doses (DDDs), defined daily cost (DDC), sequences, and drug sequence ratio (B/A) were analyzed statistically. Results The sale amounts of anti hepatitis virus nucleoside drugs in Tangshan Infectious Disease Hospital increased year by year from 2011 to 2015. The sales of lamivudine, adefovir, and entecavir were all over 90% of total sales in five years. But the trend of sales composition ratio and DDDs sort were different, the trend of sales composition ratio and DDDs sort of lamivudine and adefovir decresed, butthose of entecavir increased. The DDC of tenofovir disoproxil fumarate was maximum (DDC>100), DDC of adefovir was minimum (DDC<10). DDC of all five kinds of drugs were decreased, tenofovir disoproxil fumarate of DDC decreased significantly, and those of adefovir dipivoxil had small decline. B/A values of all anti hepatitis virus nucleoside drugs were closed to 1. Conclusion The sale amounts of of anti hepatitis virus nucleoside drugs in Tangshan Infectious Disease Hospital show a rising trend, and clinical use is becoming more and more reasonable. However, the problem of high average daily cost and poor synchronism of few drugs are still existed, which needs further efforts to strengthen the management.